TrumpLyftAlles | 0 points
MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin (2020-04-06 press release)[-] TrumpLyftAlles | 1 points
I didn't think this study warranted a new post.
Effects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle
Medicell's BEPO tech was used to inject ivermectin into 4 cows for 3 months. [This chart is mildly interesting.] (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233116/bin/parasite-27-36-fig1.jpg). I gather the tech worked. It is a very long and tedious article and difficult to understand.
I guess it's (vaguely?) similar to what they will do to test ivermectin vs covid19?!
[-] TrumpLyftAlles | 1 points
[-] TrumpLyftAlles | 1 points
A site that collects MedinCell news, with links!
https://www.finanznachrichten.de/nachrichten-aktien/medincell-sa.htm
[-] TrumpLyftAlles | 1 points
More content like OP's post.
n March 2020, MedinCell received a grant of up to $6.4 million over three years with global health agency Unitaid. The grant aims to fund the formulation and preclinical activities of a 3-month acting injectable ivermectin a drug used to treat many types of parasitic infections to neutralize the transmission vector of Malaria.3
The third path to fight Covid-19: Prevention
MedinCell announced on April 6, 2020, its Covid-19 project launched a few weeks ago5. This program aims at developing a long-acting injectable Ivermectin formulation for several months to protect people who are not infected with Covid-19 in order to break the virus chain of transmission. Such a tool could play a decisive role in the management of Covid-19 pandemic, by enabling many people around the world, especially those most exposed and at risk, to protect themselves.
"This is a third way between a treatment and a vaccine," explains Christophe Douat, CEO of MedinCell. "Historically, the time to develop vaccines has been very long. We will probably have to wait several years, and we don't know for sure the research will succeed. To date, no vaccine has ever been developed for a Coronavirus, and a virus can mutate, making the vaccine ineffective. Our product is based on a concept already used in HIV to protect populations at risk. "
Ivermectin has long been considered a safe and effective drug to treat some parasitic diseases. Its action on viruses such as SARS, rabies, influenza, HIV, Dengue or the West Nile has been proven in vivo or in vitro in the past, suggesting a potential against Covid-19.
On March 29, 2020, researchers from Monash University in Melbourne, Australia published results from a laboratory cell study showing that Ivermectin can kill the coronavirus in less than 48 hours.6
Studies have been carried out by research institutes for the past few months to assess the effectiveness of treatment using Ivermectin on hospitalized patients with Covid-19.
MedinCell published last January data showing that Ivermectin can be formulated with our BEPO technology as a long-acting for varying doses and durations of up to several months.7 The company is already developing a long-acting injectable Ivermectin formulation for several months to neutralize the malaria vector.
The success of this program is conditioned in particular by the results of future in vitro, in vivo and clinical studies. The objective of these studies will be to validate the efficacy and safety of Ivermectin against Covid-19 for prophylactic (preventive) action in humans and to determine the dose required.
At this stage, the Company is not in a position to communicate a schedule for this program and is evaluating several scenarios for future developments. The strong international mobilization to deal with the Covid-19 crisis makes it possible to foreseen accelerated developments, all the more so since Ivermectin is a molecule already widely documented and used, and that our BEPO technology is already in several clinical trials in other indications.
Oops: "makes it possible to foreseen accelerated developments." WTF does that mean?
In case of positive results of the current and future studies, MedinCell's know-how, and its connections with large industrial groups and the lead organizations and foundations for health in the world, could make it possible to eventually offer a large-scale solution to the fight against the pandemic.
Of date, no vaccine has been created for a coronavirus
[-] TrumpLyftAlles | 1 points | May 30 2020 23:34:52
The 1-page PDF can be downloaded here.
The relevant parts of the press release.
* MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of ivermectin and believes it could have a role to play in Covid-19 management.
Future clinical studies will have to confirm the action of ivermectin* on Covid-19 virus, and the potential effectiveness of a long-acting injectable on its prevention and therefore breaking the chain of transmission.
In case of positive results, a BEPO® technology based long-acting injectable ivermectin* offers a rapidly deployable and affordable solution for a global pandemic.
#About MedinCell
MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities
permalink